RET and cancer: With the new understanding of RET being a main source of pathological ROS during ischemic stroke, cancer, and age-related diseases, and the RET-induced NAD+/NADH ratio decrease being another important mediator of the biological effects of RET, new therapeutic approaches targeting the RET process or the downstream effectors of RET—both RET-ROS and the NAD+/NADH imbalance—are warranted for the treatment of ischemic stroke as well as other disease conditions where RET has been implicated, from cancer to age-related neurodegenerative diseases.